Analyst Price Target is $4.67
▲ +264.58% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Savara in the last 3 months. The average price target is $4.67, with a high forecast of $7.00 and a low forecast of $3.00. The average price target represents a 264.58% upside from the last price of $1.28.
Current Consensus is
The current consensus among 4 investment analysts is to buy stock in Savara. This Buy consensus rating has held steady for over two years.
Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.